|
Emavusertib Clinical Trials
6 actively recruiting trials across 5 locations
Also known as: AU 4948, AU-4948, CA 4948, CA-4948, CA4948, IRAK4 Inhibitor CA-4948, Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948
Duarte, California2 trials
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
City of Hope Comprehensive Cancer Center
Phase 1
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
City of Hope Comprehensive Cancer Center
Phase 1
Phoenix, Arizona1 trial
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
St. Joseph's Hospital and Medical Center
Phase 1/2
Gainesville, Florida1 trial
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
UF Health Cancer Institute - Gainesville
Phase 1
Miami Beach, Florida1 trial
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Mt Sinai Comprehensive Cancer Center
Phase 2
Tampa, Florida1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.